在非小细胞肺癌中,DUSP22通过直接去酸化AKT来抑制瘤的进展
Jingying Chen1,2, Guoqi Kang1, Weidong Lei1
1Joint National Laboratory for Antibody Drug Engineering, the First Affiliated Hospital, Henan University, Kaifeng, China.
双特异性酸酶22 (DUSP22) 解化蛋白激酶B (AKT),抑制非小细胞肺癌 (NSCLC) 细胞活力和迁移. 减少DUSP22表达与较差的患者存活率相关,表明其治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 蛋白激酶B (AKT) 对于细胞信号传递至关重要,也是癌症治疗的关键标.
- 人们对AKT的脱化理解较少,但对其调节至关重要.
- 双特异性酸酶 (DUSP22) 涉及到细胞过程,其在肺癌中的作用需要进一步阐明.
研究的目的:
- 研究AKT脱酸化的分子机制,专注于DUSP22.
- 评估DUSP22作为非小细胞肺癌 (NSCLC) 的治疗标和预后标记物的潜力.
主要方法:
- 使用GEPIA和Oncomine数据库对NSCLC细胞系和组织中DUSP22表达的分析.
- 卡普兰-梅尔分析以将DUSP22表达与患者存活率相关联.
- 评估DUSP22对NSCLC细胞系 (A549,H1299) 的抗瘤作用,使用细胞活力,迁移试验,共免疫沉和体外激酶试验.
主要成果:
- 在NSCLC细胞系和组织中,DUSP22的表达显著下调.
- 较低的DUSP22表达与肺癌患者的整体存活率较差相关.
- DUSP22通过降低AKT和p38酸化来抑制NSCLC细胞活力和迁移.
- DUSP22与AKT直接相互作用,根据其酸酶活性,在S473和T308残留处脱化它.
结论:
- DUSP22直接去酸化AKT,抑制肺癌细胞的增殖和迁移.
- 低调DUSP22与NSCLC的预后不佳有关.
- DUSP22代表了NSCLC的潜在治疗标和预后生物标志物.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation
Inhibition of Cdk Activity
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
